Trump Nominates Dr. Heidi Overton as FDA Commissioner

# What happened President Donald Trump announced the nomination of Heidi Overton, MD, PhD to serve as Commissioner of the U.S. Food and Drug Administration. She would succeed Marty Makary, who resigned in May 2026. Kyle Diamantas, JD, has been serving as acting commissioner.

# Who is Heidi Overton Dr. Overton currently serves as Deputy Assistant to the President for Domestic Policy at the White House, where she works on health care and public policy and coordinates with the Department of Health and Human Services. Her record combines clinical training, scientific research, and policy roles:

• Board-certified in general public health and preventive medicine.
• Completed a surgical oncology research fellowship and general surgery residency training at Johns Hopkins.
• Previously worked as chief policy officer at the America First Policy Institute and vice chair for the Center for a Healthy America.
• Served during the first Trump administration as a White House Fellow in the Office of American Innovation and the Domestic Policy Council.

# Industry responses Two trade groups with ties to supplements and consumer health products released supportive statements:

• American Herbal Products Association (AHPA): AHPA's president and CEO praised Overton's scientific credentials and her work on CBD policy at the White House Domestic Policy Council. AHPA said Overton consulted scientific literature and industry resources, and expressed hope her leadership would protect consumer safety while allowing innovation and expanded dietary supplement ingredients.

• Consumer Healthcare Products Association (CHPA): CHPA welcomed the nomination and highlighted Overton's experience in medicine, public health, and policy. The group noted interest in expanding Rx-to-OTC switches, consumer access to self-care options, and speeding market pathways for innovative products.

# Points of scrutiny and Senate questioning Media reports cited in the coverage show Overton has faced scrutiny on several fronts during the confirmation process and in press coverage:

• Vaccines and vaccine policy: Senate committee hearings pressed her on vaccine-related topics, according to multiple outlets.
• Mifepristone and abortion-related policy: Senators questioned her positions during hearings.
• Food safety: Her handling or views related to a recent cyclospora outbreak came under review in reporting.
• Relationship with the President: Senators asked whether she could tell the president he was wrong, reflecting questions about independence and decision-making at the FDA.

# What this means for the FDA and specific industries If confirmed, Overton would lead FDA policy at a time when trade groups are seeking expanded access to dietary supplement ingredients, more efficient pathways for consumer health products, and broader Rx-to-OTC switches. AHPA and CHPA emphasized hopes that her approach will combine scientific rigor with pro-innovation policies, particularly around CBD and self-care products.

Senate scrutiny on high-profile public health topics signals the confirmation process will probe both her technical qualifications and her willingness to make independent regulatory decisions.

# Next steps